BACM
HAE icon

Blue Arrow Capital Management’s Haemonetics HAE Stock Holding History

Blue Arrow Capital Management’s Portfolio HAE Stock Details HAE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-1,892
Closed -$71K – 183
2014
Q4 		$71K Buy
+1,892
New +$69.3K 0.01% 182

Other funds holding HAE

Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Barrow, Hanley, Mewhinney & Strauss
Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $30.5B AUM 29.95% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
WHG
Westwood Holdings Group Dallas, Texas $13.7B AUM 21.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BCIM
Black Creek Investment Management Toronto, Ontario, Canada $1.86B AUM 15.33% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Blue Arrow Capital Management's HAE Position: Q1 2015 in Review

Blue Arrow Capital Management sold out of Haemonetics (HAE) in Q1 2015, closing a stake of 1,892 shares — an estimated $71K sold.

Blue Arrow Capital Management first reported a position in HAE in Q4 2014 and held it in 1 quarter. The position peaked at $71K in Q4 2014. 169 funds tracked by Wall St. Rank hold HAE as of Q1 2015.

  • Blue Arrow Capital Management reported no remaining Haemonetics position as of Q1 2015 after selling out during the quarter.
  • Blue Arrow Capital Management sold 1,892 Haemonetics shares in Q1 2015, an estimated $71K.
  • Blue Arrow Capital Management first reported a position in Haemonetics in Q4 2014 and held it in 1 quarter.
  • Blue Arrow Capital Management's Haemonetics position peaked at $71K in Q4 2014.
  • 169 funds tracked by Wall St. Rank held Haemonetics as of Q1 2015.

Based on Blue Arrow Capital Management's 13F filing for Q1 2015, filed 15 May 2015.